

Table 1: Selected gram-positive Hospital wide antibiogram (HWA) and CF-specific antibiogram results

| | # of tested isolates (%) | % Susceptible Antibiotic Tested | | | | | |
|------------|--------------------------|---------------------------------|-----|-----|-----|---------|------|
| | | CLIN | LZD | RIF | TET | TMP/SMX | VANC |
| MSSA (HWA) | 5962 (59) | 79 | 100 | 100 | 96 | 96 | 100 |
| MSSA (CF) | 902 (9) | 71 | 99 | 99 | 96 | 99 | - |
| MRSA (HWA) | 2854 (28) | 83 | 100 | 99 | 97 | 96 | 100 |
| MRSA (CF) | 348 (4) | 39 | 99 | 94 | 97 | 99 | 100 |

Table Legend: MSSA: methicillin-susceptible *Staphylococcus aureus*, MRSA: methicillin-resistant *Staphylococcus aureus*, CMKC: Children's Mercy Kansas City, HWA: hospital wide antibiogram, CF: Cystic Fibrosis, CLIN: clindamycin, LZD: linezolid, RIF: rifampin, TET: tetracycline, TMP/SMX: trimethoprim/sulfamethoxazole, VANC: vancomycin

Table 2: CF-specific antibiogram for SA based on source

| | # of tested isolates (%) | % Susceptible Antibiotic Tested | | | | | |
|-------------------------------|--------------------------|---------------------------------|-----|-----|-----|---------|------|
| | | CLIN | LZD | RIF | TET | TMP/SMX | VANC |
| MSSA CF (Sputum) | 399 (32) | 62 | 99 | 98 | 95 | 99 | - |
| MSSA CF (Oropharyngea I Swab) | 503 (40) | 78 | 100 | 100 | 97 | 99 | - |
| MRSA CF (Sputum) | 225 (18) | 36 | 99 | 92 | 98 | 98 | 100 |
| MRSA CF (Oropharyngea I Swab) | 123 (10) | 46 | 100 | 97 | 97 | 99 | 100 |

Table Legend: MSSA: methicillin-susceptible *Staphylococcus aureus*, MRSA: methicillin-resistant *Staphylococcus aureus*, CF: Cystic Fibrosis, CLIN: clindamycin, LZD: linezolid, RIF: rifampin, TET: tetracycline, TMP/SMX: trimethoprim/sulfamethoxazole, VANC: vancomycin

Table 3: Selected gram-negative HWA and CF specific antibiogram results

| | # of tested isolates (%) | % Susceptible Antibiotic Tested | | | | | | | |
|----------|--------------------------|---------------------------------|-----|-----|-------|------|------|----------|-----|
| | | AMK | AZT | CFZ | CIPRO | GENT | MERO | PIP/TAZO | TOB |
| PA (HWA) | 1268 (73) | 99 | 96 | 96 | 96 | 93 | 98 | 96 | 97 |
| PA (CF) | 480 (27) | 71 | 79 | 91 | 90 | 71 | 93 | 91 | 87 |

Table Legend: HWA: hospital wide antibiogram, CF: Cystic Fibrosis, PA: *Pseudomonas aeruginosa*, AMK: amikacin, AZT: aztreonam, CFZ: ceftazidime, CIPRO: ciprofloxacin, GENT: gentamicin, MERO: meropenem, PIP/TAZO: piperacillin/tazobactam, TOB: tobramycin

Table 4: CF specific antibiogram for PA based on source

| | # of tested isolates (%) | % Susceptible Antibiotic Tested | | | | | | | |
|----------------------------|--------------------------|---------------------------------|--------|--------|--------|--------|--------|----------|--------|
| | | AMK | AZT | CFZ | CIPRO | GENT | MERO | PIP/TAZO | TOB |
| PA CF (Sputum) | 305 (64) | 62 | 76 | 88 | 85 | 63 | 89 | 87 | 82 |
| PA CF (Oropharyngeal Swab) | 175 (36) | 86 | 84 | 97 | 97 | 84 | 100 | 98 | 95 |
| p value | | 0.0002 | 0.2156 | 0.0287 | 0.0052 | 0.0012 | 0.0007 | 0.0055 | 0.0067 |

Table Legend: PA: *Pseudomonas aeruginosa*, CF: Cystic Fibrosis, AMK: amikacin, AZT: aztreonam, CFZ: ceftazidime, CIPRO: ciprofloxacin, GENT: gentamicin, MERO: meropenem, PIP/TAZO: piperacillin/tazobactam, TOB: tobramycin

Table 5: CF specific antibiogram for *Achromobacter* species, *Burkholderia* species and *Stenotrophomonas maltophilia*

| | # of isolates (n) | % Susceptible Antibiotic Tested (# of isolates tested) | | | |
|-------------------------------------|-------------------|---|---------|---------|----------|
| | | CFZ | CIPRO | MERO | TMP/SMX |
| <i>Achromobacter</i> species | 56 | 77 | 25 | 87 (53) | 76 (55) |
| <i>Burkholderia</i> species | 40 | 70 (37) | 65 (23) | 83 (35) | 78 (37) |
| <i>Stenotrophomonas maltophilia</i> | 149 | 20 (125) | - | - | 91 (148) |

Table Legend: CFZ: ceftazidime, CIPRO: ciprofloxacin, MERO: meropenem, TMP/SMX: trimethoprim/sulfamethoxazole